Research into COVID-19 supported by NIHR has played a pivotal role in the UK’s response to the pandemic, effective vaccines, treatments and increased knowledge. NIHR is hugely grateful to the study teams and over one million people who have enabled this to happen.
Over a third of studies that had been badged with Urgent Public Health priority status have now completed, and many other studies are well underway, due to meet their primary endpoints in the coming weeks. It remains important these are successfully completed.
There are a smaller number of new, smaller COVID-19 studies coming through which will be eligible for support through the CRN portfolio process. New COVID-19 studies will continue to be delivered and supported by the CRN following business as usual processes, and will begin to transition onto the main portfolio, with complete transition by the end of May. A new specialty group, the COVID-19 Understanding and Elimination - Trials Implementation Panel, will manage and oversee the delivery of all COVID-19 studies.